Nasser S M Ismail (Nasser Sm Ismail)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 10

Top Topics

Molecular Dynamics

Cognitive Decline

Tyrosine Kinase

Top Venues

Future medicinal chemistry

Archiv der Pharmazie

Journal of enzyme inhibition and medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Eman M Azmy, Ibrahim F Nassar, Mohamed Hagras, Iten M Fawzy, Maghawry Hegazy, Mahmoud Mohamed Mokhtar, Amr Mohamed Yehia, Nasser S M Ismail, Walaa H Lashin
New indole derivatives as multitarget anti-Alzheimer's agents: synthesis, biological evaluation and molecular dynamics. Future medicinal chemistry 15 (6) (2023)
Eman M Azmy, Ibrahim F Nassar, Mohamed Hagras, Iten M Fawzy, Maghawry Hegazy, Mahmoud Mohamed Mokhtar, Amr Mohamed Yehia, Nasser S M Ismail, Walaa H Lashin
New indole derivatives as multitarget anti-Alzheimer's agents: synthesis, biological evaluation and molecular dynamics. Future medicinal chemistry 15 (6) (2023)
Eman M Azmy, Ibrahim F Nassar, Mohamed Hagras, Iten M Fawzy, Maghawry Hegazy, Mahmoud Mohamed Mokhtar, Amr Mohamed Yehia, Nasser S M Ismail, Walaa H Lashin
New indole derivatives as multitarget anti-Alzheimer's agents: synthesis, biological evaluation and molecular dynamics. Future medicinal chemistry 15 (6) (2023)
Eman M Azmy, Ibrahim F Nassar, Mohamed Hagras, Iten M Fawzy, Maghawry Hegazy, Mahmoud Mohamed Mokhtar, Amr Mohamed Yehia, Nasser S M Ismail, Walaa H Lashin
New indole derivatives as multitarget anti-Alzheimer's agents: synthesis, biological evaluation and molecular dynamics. Future medicinal chemistry (2023)
Eman M Azmy, Ibrahim F Nassar, Mohamed Hagras, Iten M Fawzy, Maghawry Hegazy, Mahmoud Mohamed Mokhtar, Amr Mohamed Yehia, Nasser S M Ismail, Walaa H Lashin
New indole derivatives as multitarget anti-Alzheimer's agents: synthesis, biological evaluation and molecular dynamics. Future medicinal chemistry 15 (6) (2023)
Asmaa A Mandour, Eslam B Elkaeed, Mohamed Hagras, Hanan M Refaat, Nasser S M Ismail
Virtual screening approach for the discovery of selective 5α-reductase type II inhibitors for benign prostatic hyperplasia treatment. Future medicinal chemistry (2023)
Asmaa A Mandour, Ibrahim F Nassar, Mohammed T Abdel Aal, Mahmoud A E Shahin, Wael A El-Sayed, Maghawry Hegazy, Amr Mohamed Yehia, Ahmed Ismail, Mohamed Hagras, Eslam B Elkaeed, Hanan M Refaat, Nasser S M Ismail
Synthesis, biological evaluation, and in silico studies of new CDK2 inhibitors based on pyrazolo[3,4- d ]pyrimidine and pyrazolo[4,3- e ][1,2,4]triazolo[1,5- c ]pyrimidine scaffold with apoptotic activity. Journal of enzyme inhibition and medicinal chemistry 37 (1) (2022)
Ibrahim F Nassar, Mohammed T Abdel Aal, Wael A El-Sayed, Mahmoud A E Shahin, Elsayed G E Elsakka, Mahmoud Mohamed Mokhtar, Maghawry Hegazy, Mohamed Hagras, Asmaa A Mandour, Nasser S M Ismail
Discovery of pyrazolo[3,4- d ]pyrimidine and pyrazolo[4,3- e ][1,2,4]triazolo[1,5- c ]pyrimidine derivatives as novel CDK2 inhibitors: synthesis, biological and molecular modeling investigations. RSC advances 12 (23) (2022)
Mohamed Hagras, Asmaa A Mandour, Esraa A Mohamed, Eslam B Elkaeed, Ibrahim M M Gobaara, Ahmed B M Mehany, Nasser S M Ismail, Hanan M Refaat
Design, synthesis, docking study and anticancer evaluation of new trimethoxyphenyl pyridine derivatives as tubulin inhibitors and apoptosis inducers. RSC advances 11 (63) (2021)
Amna Ghith, Nasser S M Ismail, Khairia Youssef, Khaled A M Abouzid
Medicinal Attributes of Thienopyrimidine Based Scaffold Targeting Tyrosine Kinases and Their Potential Anticancer Activities. Archiv der Pharmazie 350 (11) (2017)